Pending AI has developed a comprehensive discovery platform enabled by artificial intelligence and quantum mechanics, ushering in a new paradigm of medicinal innovation where higher-quality small molecule drugs can be developed in a fraction of the time and cost. The company's capabilities include but are not limited to: 1) Generative Molecule Designer (automated and ultra-high-throughput production of novel pharmacological scaffolds), 2) Retrosynthesis Engine (rapid prediction of synthesis pathways to any given query molecule) and 3) Quantum Refinement of Protein Structures (higher-quality crystal structures for biological targets, improving the likelihood of virtual screening campaign success). Pending AI is actively seeking research-and-development partnerships with pharmaceutical companies, as well as ascertaining interest from investors in the company's upcoming investment round.